COMMUNIQUÉS West-GlobeNewswire

Rapid Micro Biosystems to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

03/09/2024 - 22:50

LEXINGTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to [...]

Protect Pharmaceutical Corp. Announces that KARINCA Logistics Merger Will Not Proceed

03/09/2024 - 22:45

ANKARA, Turkey, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Protect Pharmaceutical Corp. (OTC: PRTT) (“Company”) and Atlantic Logistics announce there will be no merger with KARINCA Logistics. The previous announcement on August [...]

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03/09/2024 - 22:40

SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics [...]

Vision Sensing Acquisition Corp. Announces Payment of Fee to Extend Period to Consummate Initial Business Combination to October 3, 2024

03/09/2024 - 22:35

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “ Company ”), a special purpose acquisition company, announced today that on August 2, 2024, its sponsor, [...]

Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)

03/09/2024 - 22:30

VANCOUVER, British Columbia, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve [...]

Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety

03/09/2024 - 22:30

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving [...]

BrightSpring Health Services Announces Definitive Agreement to Acquire Haven Hospice, Expanding Hospice Services into Florida

03/09/2024 - 22:30

LOUISVILLE, Ky., Sept. 03, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services (“BrightSpring” or “the Company”) (NASDAQ: BTSG), a leading provider of home and community-based health services for complex populations, [...]

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03/09/2024 - 22:30

CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today [...]

Cellectis présente des preuves précliniques de l’efficacité des cellules CAR T MUC1 contre le cancer du sein triple négatif tout en préservant la sécurité

03/09/2024 - 22:30

NEW YORK, 03 sept. 2024 (GLOBE NEWSWIRE) -- Cellectis (la "Société") (Euronext Growth : ALCLS - NASDAQ : CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génome TALEN [...]

Alumis to Participate in Upcoming September Investor Conferences

03/09/2024 - 22:29

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes [...]

Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference

03/09/2024 - 22:15

PARIS and CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand [...]

NANOBIOTIX PARTICIPERA À LA 26ÈME ÉDITION DE LA CONFÉRENCE ANNUELLE H.C. WAINWRIGHT GLOBAL INVESTMENT

03/09/2024 - 22:15

PARIS et CAMBRIDGE, Mass., 03 sept. 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ : NBTX – la « Société » ), société française de biotechnologie en phase de développement clinique avancé, pionnière des [...]

Codexis to Participate in Upcoming Healthcare Conferences

03/09/2024 - 22:05

REDWOOD CITY, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that management will participate in two upcoming investor conferences. The [...]

Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2025 After Market Close on September 9, 2024

03/09/2024 - 22:05

TUSTIN, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing [...]

The Iowa Clinic Signs Multi-Year Agreement with Counterpart Health to Deploy Proven AI Technology to Hundreds of Providers Across the Midwest

03/09/2024 - 22:05

FRANKLIN, Tenn., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Today, Counterpart Health, Inc . (“Counterpart”), a leading AI-powered physician enablement platform, announced a multi-year agreement with The Iowa Clinic, P.C ., one [...]

Elutia to Participate in Upcoming Investor Conferences

03/09/2024 - 22:05

SILVER SPRING, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, [...]

Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer (NMIBC) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024

03/09/2024 - 22:05

Sabine Doris Brookman-May, MD, PhD to join Aura as Senior Vice President, Clinical Development Urologic Oncology BOSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage [...]

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

03/09/2024 - 22:05

LAUSANNE, Switzerland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company [...]

Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference

03/09/2024 - 22:05

GRAND CAYMAN, Cayman Island, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company today announced that Company management [...]